Compare CODA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CODA | TLSA |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.9M | 182.7M |
| IPO Year | N/A | 2000 |
| Metric | CODA | TLSA |
|---|---|---|
| Price | $9.51 | $1.60 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 54.3K | ★ 373.4K |
| Earning Date | 01-28-2026 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 15.09 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $24,347,217.00 | N/A |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $20.84 | N/A |
| P/E Ratio | $31.70 | ★ N/A |
| Revenue Growth | ★ 29.34 | N/A |
| 52 Week Low | $5.76 | $0.63 |
| 52 Week High | $10.54 | $2.60 |
| Indicator | CODA | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 56.60 | 48.90 |
| Support Level | $8.80 | $1.47 |
| Resistance Level | $9.60 | $1.62 |
| Average True Range (ATR) | 0.44 | 0.16 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 73.89 | 58.82 |
Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company's operations are organized into two reportable segments: the Products Segment (Marine Technology Business serving the subsea market and PAL, which sells other products (acoustic hydrophones and acoustic materials to a different market); and the Services Segment (Marine Engineering Business). Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.